Jubilant life Sciences shares surged 6 according to cent on Monday, following the Noida-based pharmacompany‘s declaration approximately US regulator’s approval for Levetiracetam injection, used within thetreatment of epilepsy.
acclaim for the Levetiracetam injection will generate incremental revenue for the company, analysts stated.
With this approval, Jubilant lifestyles Sciences’ total Abbreviated New Drug software (ANDA) approvals rose to 517 in various areas globally, the agency said.
As of nine.35 a.m., Jubilant existence Sciences shares traded 4.55 in step with cent better at Rs 369 apiecein comparison to zero.07 according to cent advantage within the broader Sensex.
